Novo Nordisk A/S – Consensus Indicates Potential -3.7% Downside

Broker Ratings

Novo Nordisk A/S with ticker code (NVO) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The range between the high target price and low target price is between 81.08 and 79.78 calculating the average target price we see 80.43. Now with the previous closing price of 83.49 this would indicate that there is a downside of -3.7%. The day 50 moving average is 77.91 and the 200 day MA is 72.41. The company has a market capitalisation of $193,455m. Company Website: http://www.novonordisk.com

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson’s diseases; and bluebird bio to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp